Proximal spinal muscular atrophies (SMA) are characterised by degeneration of anterior horn cells of the spinal cord, leading to progressive symmetrical limb and trunk paralysis associated with muscular atrophy. SMA represents the second most common fatal autosomal recessive disorder after cystic fibrosis (1 in 6000 newborns).'2 The genomic region encompassing the disease gene is characterised by the presence of low copy repeats and a tendency to inherited or de novo deletions. [3] [4] [5] [6] Recently, we have identified a gene duplicated in the 5ql3 region, one of which, the survival motor neurone gene (SMN), is missing in the majority of patients. Those retaining this gene carried intragenic mutations, providing strong evidence that this gene is the SMA determining gene.78 From a practical point of view, direct SMN gene analysis makes genetic counselling much easier by eliminating the need for complex polymorphism studies. Here, we report the relevance of these recent advances for genetic counselling and prenatal diagnosis in a nonconsanguineous SMA type II family with an affected boy and a healthy brother.
PCR amplification conditions of microsatellite DNA markers at loci D5S465 (AFMl14ye7), D5S435 (cVS19), D5F149S1/S2 (C212), D5F150S1/S2 (C272), and D5S351 (1105) were as follows: denaturation at 94°C for one minute, annealing at 55°C for one minute, and extension at 72°C for one minute, for 30 cycles. The procedure used for detection of dinucleotide repeat polymorphisms has been described elsewhere.9 Gels were transferred onto a nylon membrane, then hybridised overnight at 42°C with a poly-AC probe, labelled by chemiluminescence according to the manufacturer's instructions (ECL, direct nucleic acid labelling and detection system; Amersham Life Science), and exposed to x ray films for 10 minutes. For SSCP analysis of SMN exons 7 and 8, DNA from peripheral leucocytes (200 ng) was amplified by PCR using unlabelled primers (20 pmol/1) in an amplification mixture (25 pl) containing 200 ptmol/l dNTPs and 1 U Taq polymerase (Gibco BRL). Amplified DNA was mixed with an equal volume of formamide loading dye (95% formamide, 20 mmol/l EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol). The samples (5 ,tl) were denatured for 10 minutes at 95°C, loaded onto a polyacrylamide gel (Hydrolink MDE, Bioprobe), and electrophoresed at 4°C for 18 to 24 hours at 4 W. To amplify genomic DNA containing divergent exon 7 sequences, we used oligonucleotides RIll and 541C770. To amplify genomic DNA containing divergent exon 8 sequences, we used oligonucleotides 541C960 and 541C1120. 7 Both children carried identical haplotypes using polymorphic markers flanking the SMA locus ( fig 1A) . group.bmj.com on September 30, 2017 -Published by http://jmg.bmj.com/ Downloaded from Letter to the Editor family. First, it allowed the diagnosis of SMA to be confirmed, since the affected child carried a homozygous deletion of SMN exons 7 and 8, as previously reported in more than 90% of SMA patients.4578101 Second, the direct analysis of the SMN gene and its flanking markers C2 12-C272 provided strong evidence for a de novo deletion of maternal origin and rejected the hypothesis of genetic heterogeneity since the affected and unaffected children carried different genotypes at the SMN locus. The risk for the mother ofbearing another affected child should therefore be considered to be very low. Indeed, analysis of 41 families with two affected children did not provide any evidence for germinal mosaicism using microsatellite DNA markers, suggesting that this situation is very rare (data not shown, available on request). For this reason, the combined analysis of SMN and its flanking markers C212 and C272 are still of interest for detecting de novo deletions, estimating their actual frequency, and delivering accurate prenatal prediction in SMA.
In conclusion, the use of SMN gene testing has important implications for genetic counselling in SMA families. First, it allows the diagnosis of SMA to be confirmed when a proband harbours a homozygous SMN gene deletion. In contrast, the absence of a homozygous deletion may suggest either a misdiagnosis or the presence of intragenic mutations in the SMN gene, as previously reported.78 A clinical re-evaluation of the proband and the search for intragenic mutations by screening of each SMN exon should be undertaken before making prenatal diagnosis feasible.'2 Second, the use of SMN and the closest genetic markers as probes enables detection of de novo deletions in the probands. Establishing the status of the parents at the SMN locus should be helpful in estimating the actual frequency of de novo deletions at this locus. Finally, several reports have estimated the frequency of homozygous SMN deletions in asymptomatic carriers to be below 1% (0.8%).'3'4 Moreover, these observations have been reported in the mildest form of the disease only. Consequently, fetuses harbouring homozygous SMN gene deletions should be predicted to be affected in families with severely affected probands. 
